learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forProducts matching "safety trial"
Tracking 1 products like 99 Pyrilutamide solution from by companies like MinoxidilMax. View product »Learn
5 / 25 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
Research
5 / 1000+ results
research A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia
IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
research Safety and Efficacy of Transdermal Testosterone for Treatment of Hypoactive Sexual Desire Disorder
Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
research Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Effectiveness and Safety of Hair Growth Formulation Containing Tectona Grandis L.f (Teak) Leaf Extract: A Randomized, Double-Blind, Placebo-Controlled Study on Males with Androgenic Alopecia
Teak leaf extract may effectively and safely promote hair growth in males with androgenic alopecia.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
Community Join
5 / 678 resultscommunity When are the long term safety trial results for pyrilutamide due to be released?
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community No side effects on pyrilutamide / KX-826 so far
User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.
community I spoke to the Guy who did the Ru58841 (PSK-3841) research
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.